Terms ending in 2035
Every in-force patent on BioAtla Inc.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,683,048 | Antibody Molecules to PD-1 and Uses Thereof In force · High confidence | Novartis AG | In force | High confidence | |
| US 9,815,898 | Antibody Molecules to PD-1 and Uses Thereof In force · High confidence | Novartis AG | In force | High confidence | |
| US 9,908,936 | Antibody Molecules to LAG-3 and Uses Thereof In force · High confidence | Immutep S.A.S. | In force | High confidence | |
| US 12,252,535 | Antibody Molecules to LAG-3 and Uses Thereof In force · High confidence | Immutep S.A.S. | In force | High confidence | |
| US 12,600,777 | Combination Therapies Comprising Antibody Molecules to LAG-3 In force · Low confidence | Novartis AG | In force | Low confidence | |
| US 10,711,060 | Antibody Molecules to LAG-3 and Uses Thereof In force · High confidence | Novartis AG | In force | High confidence | |
| US 10,329,556 | Conditionally Active Biological Proteins In force · High confidence | BioAtla, Inc. | In force | High confidence | |
| US 10,752,687 | Antibody Molecules to PD-1 and Uses Thereof In force · High confidence | Novartis AG | In force | High confidence | |
| US 9,988,452 | Antibody Molecules to PD-L1 and Uses Thereof In force · High confidence | Novartis AG | In force | High confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by BioAtla Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.